caa a22 4500 445299150 CHVBK 20180317142551.0 cr unu---uuuuu 170323e20100901xx s 000 0 eng 10.1007/s11940-010-0082-9 doi (NATIONALLICENCE)springer-10.1007/s11940-010-0082-9 Triptans: Where Things Stand [Elektronische Daten] [Alan Cole, Michael Marmura] Opinion statement: Triptans, selective serotonin receptor agonists, were developed almost 20years ago and represented a major breakthrough in the treatment of acute migraine attacks. Since then, the triptans have become first-line agents for most patients with migraine, both with and without aura, unless contraindicated. This article reviews the development of triptans, discusses reasons for their success or failure, and examines the limitations and controversies surrounding this class of medication. Springer Science+Business Media, LLC, 2010 Cole Alan Thomas Jefferson University, 111 South 11th Street, Suite 8130, 19107, Philadelphia, PA, USA aut Marmura Michael Thomas Jefferson University, 111 South 11th Street, Suite 8130, 19107, Philadelphia, PA, USA aut Current Treatment Options in Neurology Current Science Inc. 12/5(2010-09-01), 454-463 1092-8480 12:5<454 2010 12 11940 https://doi.org/10.1007/s11940-010-0082-9 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11940-010-0082-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Cole Alan Thomas Jefferson University, 111 South 11th Street, Suite 8130, 19107, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Marmura Michael Thomas Jefferson University, 111 South 11th Street, Suite 8130, 19107, Philadelphia, PA, USA aut NATIONALLICENCE 773 0- Current Treatment Options in Neurology Current Science Inc 12/5(2010-09-01), 454-463 1092-8480 12:5<454 2010 12 11940 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer